Clinical outcomes and safety of intra‐articular 2.5% polyacrylamide hydrogel for knee osteoarthritis: A systematic review and meta‐analysis
Journal of Experimental Orthopaedics · 2026-10 · 13 (4)
DOI: 10.1002/jeo2.70991 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Experimental Orthopaedics, online erschienen am 18.11.2026. Verfasst von Marc Daniel Bouchard und 6 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Polyacrylamide hydrogel (PAAG) is an increasingly used non‐degradable intra‐articular treatment for symptomatic knee osteoarthritis (OA). This systematic review and meta‐analysis evaluated its clinical effectiveness, durability, and safety, including comparative outcomes, and subsequent total knee arthroplasty (TKA).
Methods
In accordance with PRISMA guidelines, MEDLINE, Embase, and Emcare were searched from inception to August 5, 2026. Clinical studies evaluating intra‐articular 2.5% PAAG for adult knee OA were included. Random‐effects meta‐analyses using restricted maximum likelihood with Hartung–Knapp adjustment pooled mean within‐group changes from baseline in 0‐to‐100 WOMAC pain, stiffness, and physical function scores. Other outcomes were synthesised descriptively.
Results
Nine reports representing seven independent study populations and 1017 PAAG‐treated patients were included. Meta‐analysis of four studies demonstrated improvements at 12 months in WOMAC pain (mean change [MC], −15.15; 95% confidence interval [CI], −20.13 to −10.18; I 2 = 82.2%), stiffness (MC, −12.46; 95% CI, −17.95 to −6.96; I 2 = 72.3%), and physical function (MC, −12.95; 95% CI, −19.03 to −6.87; I 2 = 84.4%). Improvements were reported from 13 to 24 months and persisted to 5 years in two linked extension studies. Meta‐analysis of three comparative studies demonstrated an improvement in pain favouring PAAG at 12 months (Hedges g, −0.30; 95% CI, −0.55 to −0.05; p = 0.035; I 2 = 0%). Post‐injection pain, effusion, and swelling occurred in 10.7%–16.6%. Superficial and deep infection occurred in 1.0% and 0.6%, respectively, in one study, while subsequent TKA occurred in 20.1% of age‐eligible knees over 2 years in another.
Conclusions
Intra‐articular 2.5% PAAG was associated with clinically relevant improvements in pain, stiffness, and physical function at approximately 1 year, with sustained improvement reported through 5 years. However, predominantly uncontrolled evidence limits attribution to PAAG, and comparative evidence has not established superiority over other intra‐articular treatments. Further randomised controlled trials are needed to establish comparative efficacy and confirm long‐term safety and durability. Level of Evidence Level IV.
Zitieren
APA
Bouchard, M. D., Gilbert, J., Ade‐Conde, M., Duru, D. O., Vivekanantha, P., Wood, T. J., & Khan, M. (2026). Clinical outcomes and safety of intra‐articular 2.5% polyacrylamide hydrogel for knee osteoarthritis: A systematic review and meta‐analysis. Journal of Experimental Orthopaedics, 13(4). https://doi.org/10.1002/jeo2.70991
Vancouver
Bouchard MD, Gilbert J, Ade‐Conde M, Duru DO, Vivekanantha P, Wood TJ, et al. Clinical outcomes and safety of intra‐articular 2.5% polyacrylamide hydrogel for knee osteoarthritis: A systematic review and meta‐analysis. Journal of Experimental Orthopaedics. 2026;13(4). doi:10.1002/jeo2.70991
BibTeX
@article{Bouchard2026,
author = {Bouchard, Marc Daniel and Gilbert, Justin and Ade‐Conde, Michael and Duru, Dave Osinachukwu and Vivekanantha, Prushoth and Wood, Thomas J. and Khan, Moin},
title = {Clinical outcomes and safety of intra‐articular 2.5% polyacrylamide hydrogel for knee osteoarthritis: A systematic review and meta‐analysis},
journal = {Journal of Experimental Orthopaedics},
year = {2026},
volume = {13},
number = {4},
doi = {10.1002/jeo2.70991}
}
EUVIMED